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A new strategy has emerged to improve healing of bone
defects using exogenous glycosaminoglycans by increasing the
effectiveness of bone-anabolic growth factors. Wnt ligands play
an important role in bone formation. However, their functional
interactions with heparan sulfate/heparin have only been inves-
tigated in non-osseous tissues. Our study now shows that the
osteogenic activity of Wnt3a is cooperatively stimulated through
physical interactions with exogenous heparin. N-Sulfation and
to a lesser extentO-sulfation of heparin contribute to the phys-
ical binding and optimal co-stimulation of Wnt3a. Wnt3a-hep-
arin signaling synergistically increases osteoblast differentia-
tion with minimal effects on cell proliferation. Thus, heparin
selectively reduces the effective dose of Wnt3a needed to
elicit osteogenic, but not mitogenic responses. Mechanistically,
Wnt3a-heparin signaling strongly activates the phosphoinosi-
tide 3-kinase/Akt pathway and requires the bone-related tran-
scription factor RUNX2 to stimulate alkaline phosphatase activ-
ity, which parallels canonical -catenin signaling. Collectively,
our findings establish theosteo-inductive potential of a heparin-
mediated Wnt3a-phosphoinositide 3-kinase/Akt-RUNX2 sig-
naling network and suggest that heparan sulfate supplementa-
tion may selectively reduce the therapeutic doses of peptide
factors required to promote bone formation.
Improved anabolic strategies are required for clinical thera-
pies that treat skeletal fractures and bone loss. At present, the
in vivo efficacy of bone anabolic factors (e.g. BMP2,3 parathy-
roid hormone, and Wnts) is limited, and new molecular
approaches to improve the effectiveness and selectivity of
osteo-inductive extracellular ligands are desirable. Results from
our group and others suggest that glycosaminoglycans (GAGs)
and in particular heparan sulfate (HS) and heparin are potent
co-stimulators of osteogenic signaling pathways, including
BMP2-Smads and FGF-FGFR-MAPK (1–7). Thus, the oppor-
tunity arises to leverage the stimulatory properties of HS-de-
rived compounds as adjuvants for osteo-inductive therapies.
The direct interaction of Wnts with heparin, which has
allowed for the affinity purification of Wnt3a (8, 9), strongly
suggests that it may also modulate the bone-promoting activity
of Wnts. Wnt proteins are a group of cysteine-rich secreted
glycolipoproteins of which at least 19members have been iden-
tified in mammals (10). Wnts bind to serpentine receptors of
the Frizzled family and their co-receptor, low density lipopro-
tein receptor-related protein 5/6 (LRP5/6). Several studies have
shown that loss-of-function mutations in Wnt signaling com-
ponents (e.g. LRP5) result in low bone mass and subsequent
osteoporosis in both human patients and murine models (11,
12). Conversely, gain-of-function mutations in the LRP5 gene
cause increased bonemass (13), whereas loss of theWnt antag-
onist sFRP1 (secreted frizzled-related protein 1) increases tra-
becular bone mineral density and volume (14).
Wnt/Frizzled/LRP5 activation on the plasmamembrane ini-
tiates a canonical cascade that is characterized by the accumu-
lation and nuclear transportation of -catenin. Nuclear -
catenin in turn activates the transcription factors lymphoid
enhancer binding factor 1 (LEF1)/T cell-specific factor (TCF)
(15, 16). The osteogenic ligandWnt3a induces osteoblast mat-
uration and extracellular matrix mineralization in multipotent
progenitor cells via the -catenin pathway (11, 17). The pro-
moters of ALP (18) and the osteogenic transcription factor
RUNX2 each contain LEF1/TCF binding sites (19), indicating
that these genes are direct and highly relevant targets of
canonical Wnt--catenin-LEF1/TCF signaling. Wnt-depen-
dent induction of RUNX2 (19), subsequent binding of RUNX2
to LEF1/TCFproteins (19), and enhanced expression of proteo-
glycans and HS-modifying enzymes (20, 21) may together pro-
vide an effective feed-forward loop that sustains expression of
osteogenic biomarkers to stimulate osteogenesis (19).
Cross-talk between Wnts and other ligands, such as the
FGFs, BMPs, and insulin-like growth factors (IGF) is important
for the progression of osteogenesis. Inmesenchymal progenitor
cells, the integrity of canonical Wnt (Wnt3a andWnt1) signal-
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ing is required tomaintain cellular responsiveness to the osteo-
inductive effects of BMP2 (17). Interestingly, FGF1 has been
reported to antagonize the Wnt pathway in osteoblasts, which
may contribute to the disturbed osteoblast maturation seen in
bone pathologies resulting from the aberrant activation of FGF
signaling (22, 23). The phosphoinositide 3-kinase (PI3K)/Akt
cascade also plays a critical role in osteoblast differentiation and
synergizes withWnt signaling (24, 25). BecauseWnts as well as
FGFs BMPs, and IGF each interact distinctly with GAGs, it is
necessary to establish which signaling pathways respond to
exogenous administration of a given ligand (e.g. Wnt) with a
given fraction of heparan sulfate.
Heparan sulfates are unbranched polysaccharides consisting
of repeating disaccharide units with N-, 2-O-, or 6-O-sulfate
residues, the negatively charged groups bound to positively
charged proteins. Heparin is a highly sulfated GAG and, thus,
avidly binds to a range of growth factors, includingWnts. Hep-
arin-growth factor interactions control the activities of suscep-
tible ligands and in particular their interactions with cognate
receptors, so dictating mesenchymal lineage progression and
cell behavior. Heparin (and the less sulfated heparan sulfates)
facilitates the binding of FGF2 to FGFRs, so augmenting osteo-
blast proliferation and differentiation (1–5). These GAGs also
enhance the activity of BMPs, osteoinductive growth factors
that have been clinically approved for spinal fusion, in part by
protecting them from enzymatic attack or structural antago-
nists (6, 7).
Although Wnt signaling and HS/heparin have osteogenic
potential and the interaction betweenWnts and these sugars is
known, no previous studies have provided direct evidence how
the Wnt-HS interaction affects bone formation. Moreover,
chronic heparin treatment in patients has been linked to osteo-
porosis, indicating that current models for the postulated bio-
logical interactions between Wnt and GAGs during bone for-
mation are fundamentally incomplete. Notably, heparin can be
either a positive or a negative regulator of canonical Wnt sig-
naling in non-osseous tissues (26, 27). Our study now clearly
resolves the biological function of Wnt-heparin interactions in
bone tissue. The data establishes that in addition to canonical
-catenin signaling, Wnt3a and heparin cooperate to invoke a
potent osteogenic response that involves the synergistic acti-
vation of the non-canonical PI3K/Akt/RUNX2 pathway to
promote osteoblastic differentiation. These findings provide
an empirical rationale for the development of pre-transla-
tional studies that use heparin as an adjuvant therapy for
skeletal regeneration.
EXPERIMENTAL PROCEDURES
Chemicals and Inhibitors—LY294002, SU5402, and cyclo-
heximide were obtained from Calbiochem. Protease inhibitor
cocktails and other chemicals were purchased from Sigma.
Cell Culture—Murine pre-osteoblast MC3T3-E1 cells and
myoblasticC2C12 cellswere obtained fromATCC.RUNX2/
murine calvarial-derived osteoprogenitor cellswere established
in a previous study (28). MC3T3-E1 and RUNX2/ cells were
maintained in -minimum essential medium (Invitrogen) sup-
plemented with 10% fetal calf serum (HyClone), antibiotics
(Invitrogen), 1 mM sodium pyruvate (Invitrogen), and 2 mM
L-glutamine (ATCC). C2C12 cells were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen) containing 10% fetal calf
serum and antibiotics. For assays, sodium pyruvate was re-
moved from themedium forMC3T3-E1 and RUNX2-null cells
and the fetal calf serum was reduced to 5% for C2C12 cells.
Primary rat calvarial osteoprogenitor cells (rOB) were isolated
by collagenase/EDTAdigestion as described previously (5). The
fraction enriched with osteoprogenitors was maintained in the
same medium as that of MC3T3-E1 cells except for additional
supplementation with 0.25 mg/ml amphoterin B. In conditions
where cells were treated with both Wnt3a (R&D Systems) and
heparin (Iduron), these two reagents were incubated in a sterile
Eppendorf tube at room temperature for 20 min before appli-
cation to the cell layer.
Immunofluorescence and Confocal Microscopy—Cells grown
on chamber slides until reaching 40–50% confluence were
treated with 50 ng/ml Wnt3a for 6 h. The cells were then fixed
in 4% paraformaldehyde for 20 min, blocked in 2% BBX (0.1%
Triton X-100, 0.1% bovine serum albumin, 250 mM NaCl, pre-
pared in phosphate-buffered saline) for 30 min and incubated
with amonoclonal antibody against-catenin (BDBiosciences)
followed by another incubation with a fluorescein isothiocya-
nate-conjugated anti-mouse IgG (Sigma) for 1 h per incubation.
Non-specifically bound molecules were removed by rinsing in
BBX at each step. Thereafter, 4,6-diamidino-2-phenylindole
nuclear staining (Invitrogen) was performed for 5 min. Labeled
cells were visualized using a Zeiss LSM 5 Pascal laser scanning
microscope (Carl ZeissMicroImaging). Images were converted
to the tagged information file (TIF) format and prepared with
Adobe Photoshop software.
Luciferase Reporter Assay—To determine LEF1/TCF tran-
scription activity, 0.4 g of the reporter plasmids TOP-FLASH
or FOP-FLASH (Upstate Biotechnology) were transfected into
40,000 cells with Lipofectamine 2000 (Invitrogen). 4 ng (1% of
TOP-FLASH) of Renilla-LUC reporter vector (Promega) was
co-transfected as control for transfection efficiency. Cells were
treated 4 h post-transfection as indicated with different ligands
for another 24 h before luciferase activity was determined using
the Dual-Luciferase assay kit (Promega) according to the man-
ufacturer’s instructions. Briefly, cells were lysed in PLB buffer
supplied, and the activities of firefly (produced by TOP-FLASH
or FOP-FLASH) and Renilla luciferases were measured se-
quentially in each sample. The TOP-FLASH luciferase activi-
ties were calculated as -fold stimulation after normalization to
Renilla-LUC activity and FOP-FLASH activity. To determine
RUNX2 transcription activity, cells were transfected with 0.4
g of the reporter plasmid 6xOSE-LUC vector (29) and 4 ng of
Renilla-LUC reporter vector for 24 h before the indicated treat-
ments. Luciferase activity was assayed as described above 48 h
post-treatment. To assess the transcriptional effects of BMP
signaling, cells were transfected with 0.8 g of Id1 promoter
luciferase reporter, which contains a BMP-responsive element
(a generous gift fromDr. Bruno Reversade, Institute ofMedical
Biology, A*STAR, Singapore) and 8 ng of Renilla-LUC vector
for 6 h before treatment with Wnt3a and heparin for another
24 h. Luciferase activity was then assayed as described above.
Heparin-Sepharose Bead Precipitation Assay—The interac-
tion betweenWnt3a andheparinwas detected by the amount of
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Wnt3a bound to heparin-Sepharose beads. Free heparin or des-
ulfated heparins (Iduron) was used to compete with heparin-
Sepharose for Wnt3a binding. Based on information provided
by the supplier, the efficiency of desulfation of N-, 2-O-, and
6-O-desulfated heparins is 92, 95, and 90%, respectively. All
selectively desulfated heparins retain normal content of other
non-targeted sulfate groups, with the exception of 6-O-desul-
fated heparin, which retains normal content of N- but a 25%
loss of 2-O-sulfates. Wnt3a (50 ng) was incubated with 40 l of
75% heparin-Sepharose CL 6B slurry (Amersham Biosciences)
in 100 l of phosphate-buffered saline in the presence or
absence of 50 g/ml unmodified heparin or selectively desul-
fated heparins for 20 min at 4 °C. The beads were then washed
twice with phosphate-buffered saline, and the bound Wnt3a
was eluted by Laemmli buffer (Sigma). Wnt3a was detected
using anti-Wnt3a antibody by Western blot analysis.
Heparin-Wnt3a Binding Assay—To investigate Wnt3a-
binding properties to heparin, an enzyme-based assay was per-
formed using the specially prepared GAG binding plates (Idu-
ron) as per the manufacturer’s instructions. Briefly, the plates
were first coated with various amounts of unmodified heparin
or selectively desulfated heparins (Iduron) in the standard assay
buffer provided. After blocking in 0.2% gelatin, 50 ng/mlWnt3a
was applied to the plate. The heparin-coated wells not subject
toWnt3a served as blank controls. To eliminate the nonspecific
binding of Wnt3a to the plates, wells without heparin coating
but subject to Wnt3a were also used as blank controls. Wnt3a
binding to heparin was then detected by its specific antibody
conjugated with biotin (Abcam). Biotin was further boundwith
ExtrAvidin-AP (alkaline phosphatase) followed by incubation
with p-nitrophenyl phosphate, which is the chromogenic sub-
strate of AP and gives a yellow-color product detectable at 405
nm using a Victor3 multilabel plate reader (PerkinElmer Life
Sciences). The entire assaywas performed at room temperature
or 37 °C as instructed and protected from light, with each step
followed by extensive washing to remove nonspecific interac-
tions. The experimental readings were adjusted by subtracting
background (determined from blank readings) and analyzed.
Western Blot Analysis—Cells were treated as indicated and
denatured in Laemmli buffer at 95 °C for 5 min. Protein lysates
(20 l) were separated by SDS-PAGE, and proteins were trans-
ferred to nitrocellulose membranes. Membranes were blocked
with 5% nonfat dry milk or bovine serum albumin in TBST (10
mM Tris-base, 150 mM NaCl, pH 7.6, 0.1% Tween 20) and then
incubated with the corresponding primary antibody and sec-
ondary antibody for 1 h at each step. The blot was rinsed with
TBST between each incubation to remove any non-specifically
bound molecules. Monoclonal antibody against -catenin,
RUNX2, or actin was purchased from BD Biosciences, MBL, or
Chemicon International, respectively. Polyclonal antibodies
against Wnt3a, p85, phosphorylated p85, Akt, phosphorylated
Akt, and phosphorylated glycogen synthase kinase 3 were
supplied by Cell Signaling Technology. Anti-mouse or rabbit
secondary antibodies conjugated to horseradish peroxidase
were from Amersham Biosciences. The horseradish peroxi-
dase-bound protein bands were then visualized using the
enhanced chemiluminescence (ECL) kit according to the man-
ufacturer’s instructions (Amersham Biosciences). For reblot-
ting, membranes were stripped at 37 °C for 15–30 min in strip-
ping buffer (Pierce). Efficacy of stripping was determined by
re-exposure of the membranes to ECL. Clear membranes were
reblocked and immuno-labeled as desired. The intensity of pro-
tein bands on blots was quantified by densitometric scanning
(Epson V500, Epson) and analyzed by Quantity One software
(Bio-Rad).
Proliferation Assay—MC3T3-E1 cells were plated in tripli-
cate at 30,000 cells/cm2 in 48-well plates, and the rate of prolif-
eration was determined bymonitoring cell number after 3 days
using the GUAVA PCA-96 Viacount system (GUAVA Tech-
nologies). Briefly, cells were trypsinized at 37 °C for 5min, tryp-
sin was inactivated, and cells were stained with GUAVA Flex
dye (supplied by the manufacturer). The cell suspension was
transferred to a 96-well plate with a U-shaped bottom (Nunc)
and counted in triplicate using the GUAVAViacount program.
ALPActivity Assay—Cells seeded in triplicate at 30,000 cells/
cm2 were treated as indicated. Cells were then lysed in radio-
immunoprecipitation assay buffer (150 mM NaCl, 10 mM Tris,
pH 7.4, 2 mM EDTA, 0.5% Nonidet P-40, 0.1% SDS, 1% Triton
X-100, protease inhibitor mixture), and the protein concentra-
tion was determined using the BCA protein assay kit (Pierce)
following the manufacturer’s instructions. ALP activity was
determined using equal amounts of total protein. Briefly, 20g
of proteins were incubated with 40 l of assay buffer including
substrate p-nitrophenyl phosphate (Zymed Laboratories Inc.)
at 37 °C for 1 h. Calf intestinal alkaline phosphatase (New Eng-
land Biolabs) was used as positive control. The absorbance at
405 nm was measured using the Victor3 1420 multilabel coun-
ter (PerkinElmer Life Sciences).
Real-time Quantitative PCR Analysis—The mRNA levels of
target genes were quantitated using reverse transcription and
the TaqMan real-time PCR method. MC3T3-E1 cells were
grown in triplicate and treated with either 50 ng/ml Wnt3a, 50
g/ml heparin, or their combination for 72 h. Total RNA was
isolated using the NucleospinTM RNA extraction kit (Mach-
erey-Nagel) as instructed by the manufacturer. The quality and
quantity of total RNA was determined by gel electrophoresis
and a GeneQuant spectrophotometer (Amersham Biosciences).
Total RNA (1 g) was reverse-transcribed into cDNA using
SuperScript VILOTM cDNA synthesis kit (Invitrogen). Ex-
pression levels of target genes were determined using 20 ng of
each cDNA sample assayed in triplicate and amplified with the
ABI Prism 7500 sequence detection system (PerkinElmer Life
Sciences). The primers and probes for RUNX2, osterix, ALP
(liver/bone/kidney isoenzyme), bone sialoprotein, osteocalcin,
c-Myc, FGFR1, FGFR2, FGFR3, cyclinB, cyclinD, cyclinE,
CDK2, CDK4, p21, p27, p57, and housekeeping gene actin were
pre-designed by Applied Biosystems. As a control for the input
amount, each cDNA sample was also amplified using the pre-
designedprimer andprobe for actin (AppliedBiosystems).Data
were analyzed using the Applied Biosystems Sequence Detec-
tor software.
Plasmid Construction and Transfection—A human RUNX2
cDNA (30)was subcloned into pcDNA3.1 () (Invitrogen), and
the integrity of the RUNX2 protein coding sequence was con-
firmed by DNA sequencing (BSF DNA sequencing facility,
A*STAR, Singapore). The pcDNA3-RUNX2 vector (1 g) was
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then transfected into RUNX2/ cells plated at 10,000 cells/
cm2 in a 6-well plate using the GeneJammer transfection re-
agent (Stratagene) as per the manufacturer’s instructions. Cells
transfected with the empty vector pcDNA3.1 (-) were used as
negative control. Cells were re-plated at 24 h post-transfection
at a density of 2500 cells/cm2 and then treated for 72 h with 50
ng/ml Wnt3a and/or between 0.5–50 g/ml heparin as indi-
cated before harvesting.
RNA Interference—MC3T3-E1 cells seeded at 20,000 cells/
cm2 in 24-well plates were transfected with 50 pmol of siRNA
specific for the target genes or scrambled siRNA as the negative
control using Lipofectamine 2000 (Invitrogen). The com-
mercially synthesized siRNAs were purchased from Qiagen
(Germany) and used as described in the protocols provided
by the manufacturer. For each target gene, two or three
siRNAs were tested, and the siRNAwith the most potent and
specific gene silencing effect was selected for further studies.
Cells were treated as indicated 24 h post-transfection with
siRNAs.
Statistical Analysis—Each experiment was repeated three
times, and data were expressed as the mean S.E. Differences
among treatments were analyzed by Student’s t test or analysis
of variance. Significant differences were considered as those
with a p value of0.05.
RESULTS
Wnt3a and Heparin Synergistically Increase ALP Activity—
Wnt3a activates osteogenic differentiation in both multipotent
mesenchymal cells and pre-committed osteoblasts (17, 31, 32).
Stimulation of the canonical Wnt pathway in response to
Wnt3a was reflected by a dose-dependent increase in the tran-
scriptional activity of LEF1/TCF that reaches maximal potency
at 50 ng/ml (within the dose range tested) as measured by tran-
sient transfection assays with the TOP-FLASH reporter in
MC3T3-E1 cells (Fig. 1A). Nuclear translocation of -catenin
(labeled with fluorescein isothiocyanate) was evident upon
stimulation with 50 ng/ml Wnt3a (for 6 h) as visualized by
immunofluorescence and confocal microscopy (Fig. 1B). As
expected, -catenin was detected in the cytoplasm of cells at
peripheral sites of cell-cell contact in the absence of Wnt3a,
whereas -catenin was predominantly detected in the nucleus,
which was visualized by chromatin staining using 4,6-di-
amidino-2-phenylindole in Wnt3a-stimulated cells (Fig. 1B).
Exogenous Wnt3a was a potent ligand for induction of ALP
activity in mesenchymal progenitor cells (C2C12) but was not
effective in stimulating ALP activity in MC3T3-E1 preosteo-
blasts (Fig. 1C), as had also been observed previously (17). The
ineffectiveness of Wnt3a in stimulating ALP in MC3T3-E1
osteoblasts was notable considering that the dose we applied
(50 ng/ml) was optimal for the transcriptional activation of
-catenin-LEF1/TCF complexes and nuclear translocation
(Fig. 1,A andB). Thus,Wnt3a signaling by itself is ineffective in
stimulating ALP activity in MC3T3-E1.
Wnt signaling can be regulated by either HS or heparin (26,
27), GAGs that promote the osteogenic activity of BMP2 and
BMP7 and potentiate bone formation (6, 7, 33). Heparin binds
toWnt3a (9) and, thus,may enhance the osteogenic potential of
Wnt. Indeed, co-incubation ofMC3T3-E1 cells with both exog-
enous heparin andWnt3a, which had been preincubated for 20
min to allow complex formation, resulted in a synergistic and
dose-dependent elevation of ALP activity (Fig. 2A). Maximal
ALP activity was increased by 2–3-fold compared with either
Wnt3a or heparin treatment alone. This co-stimulation of ALP
activity byWnt3a andheparinwas also observed inC2C12mes-
enchymal progenitors and primary calvarial osteoprogenitor
(rOB) cells (Fig. 2, B and C).
AsWnt signaling stimulates osteoblast proliferation, we next
examined whether heparin increases the mitogenic effect of
Wnt3a while enhancing its osteogenic potential. Wnt3a mod-
estly increased cell number (1.5-fold) after 3 days of stimula-
tion in cultures of actively growing MC3T3-E1 (supplemental
Fig. S1A). However, rather than increasing cell proliferation,
heparin reducedWnt3a-stimulated cell expansion aswell as the
basal MC3T3-E1 growth rate (supplemental Fig. S1A). Simi-
larly, heparin did not synergize with Wnt3a to increase cyclin/
CDK (cyclins A, B, D, and E as well as CDK2 and CDK4) ex-
pression or suppress cell cycle inhibitors (p21, p27, p57)
(supplemental Fig. S1, B and C). The effect of heparin on
selected cell cycle regulators (cyclinA2, B1, p21, or p57) was
opposite that observed for Wnt3a, consistent with a moderate
antagonism of heparin for Wnt3a-dependent cell growth
(supplemental Fig. S1A). In summary, heparin synergizes with
Wnt3a to promote its osteogenic activity but not its mitogenic
activity.
N-Sulfation of Heparin Is Critical for ItsWnt3a Binding Abil-
ity and Biological Activity—The polysaccharide chains of hep-
arin are heavilymodified by sulfation onN, 2-O, and 6-O groups
(Fig. 3A) (34), which create negative charge patterns that attract
particular basic amino acid motifs in heparin-binding proteins
FIGURE 1. Wnt3a is not sufficient to stimulate ALP activity in MC3T3-E1
cells. A, Wnt3a stimulated LEF1/TCF transcription activity in MC3T3-E1 cells.
B, Wnt3a induced nuclear translocation of -catenin in MC3T3-E1 cells that
was assessed by immunofluorescence. Merged images of -catenin and
nuclear 4,6-diamidino-2-phenylindole (DAPI) staining were shown (green,
-catenin; blue, 4,6-diamidino-2-phenylindole). Bar, 10 m. C, Wnt3a stimu-
lated ALP activity in C2C12 but not in MC3T3-E1 cells. Both cells were treated
by 50 ng/ml Wnt3a for 72 h before the ALP activity was assayed.
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(35). To assess the importance of different sulfate groups for the
interaction of heparin with Wnt3a, we performed binding
assays in which heparins selectively depleted for one type of
sulfation were used as binding competitors. Unmodified hepa-
rin immobilized to Sepharose beads precipitates Wnt3a upon
centrifugation (Fig. 3B). Free unmodified heparin competed
with the heparin-Sepharose for Wnt3a binding, thus signifi-
cantly decreasing the amount ofWnt3a precipitated upon cen-
trifugation (Fig. 3B). Importantly, desulfated heparins were less
potent than unmodified heparin in competing for the binding
between heparin-Sepharose and Wnt3a (Fig. 3B). N-Sulfate-
deficient (-N) heparin does not compete with heparin-Sepha-
rose for Wnt3a binding, indicating that N-sulfation is essential
for the Wnt3a-heparin interaction. For comparison, loss of
2-O-sulfate (-2-O) reduced the binding of Wnt3a to heparin-
Sepharose, whereas -6-O heparin only partially competed for
Wnt3a binding.
The relative affinity of these sulfate groups to Wnt3a was
further determined using a plate with a modified surface that
absorbs heparin/GAGs without altering the ligand binding
property of these sugars. Unmodified heparin was able to bind
50 ng/mlWnt3a (A405 1.1) (Fig. 3C). In contrast, themaximal
binding capacity of either -2-O or -6-O heparin for Wnt3a
was only about 30 ng/ml (A405  0.6) (Fig. 3C). Therefore, the
overall binding ability of heparin is compromised by loss of
O-sulfation. More importantly, -N heparin failed to bind
Wnt3a even at very high concentrations (150 g/ml). The
absorbance remained around 0.1 regardless of the amount of
heparin, indicating background nonspecific binding and the
absence of appreciable affinity of -N heparin for Wnt3a.
Hence, N-sulfation is crucial for the heparin-Wnt3a interac-
tion. Moreover, our results show that 0.05 g/ml unmodified
heparin suffices for achieving half-maximal binding of Wnt3a,
but 10–100-fold higher amounts are required with desulfated
heparins (respectively, 0.5 g/ml -2-O or 1.5–5 g/ml -6-O
heparin; A405  0.5 for unmodified heparin; A405  0.3 for
desulfated heparin). Therefore, the relative affinity of heparin
for Wnt3a is decreased by an order of magnitude upon 2-O-
sulfate deletion and by up to 2 orders of magnitude upon 6-O-
sulfate deletion. Consequently, the relative binding strength of
the sulfate groups in heparin for Wnt3a is N-  6-O-  2-O-
sulfation. However, 6-O-desulfated heparin also bears a25%
loss of 2-O-sulfates, which might contribute to its apparent
lower affinity to Wnt3a than 2-O-desulfated heparin. A more
definitive interpretation of the roles of 6-O versus 2-O sulfation
in heparin must await the availability of purer desulfated
heparins.
We further examined whether the sulfate groups were also
important for the biological activity of heparin. Depletion of
any of the three sulfate motifs in heparin resulted in a large
decrease of Wnt3a-heparin-induced ALP activity, albeit the
loss of N-sulfation had a more pronounced effect than that of
2-O- or 6-O-sulfation (Fig. 3D). These data indicate thatN-sul-
fation, and to a lesser extent O-sulfation, is required for the
osteogenic activity of Wnt3a-heparin complexes, consistent
with the relative affinities of desulfated heparins as determined
by the binding assays.
-Catenin Contributes to the Synergistic Activation of ALP by
Wnt3a and Heparin—As we have shown that heparin also
interacts with Wnt3a to activate ALP, it is necessary to further
address whether -catenin is a key mechanistic component of
this pathway (Fig. 4A). Canonical Wnt signals are transduced
through -catenin that contributes to basal ALP activity in
MC3T3-E1 cells (17). The interaction of heparin with Wnt3a
may enhance the activation of -catenin and, thus, generate
more potent osteogenic signals. We next employed RNA inter-
ference of -catenin to inhibit its expression (Fig. 4B). Wnt3a
stimulation of the LEF1/TCF-dependent reporter gene was
diminished by preincubation with -catenin siRNA, establish-
ing the successful suppression of canonical Wnt signaling (Fig.
4C). Basal ALP activity was also decreased in -catenin-de-
pleted cells (Fig. 4D), consistent with previous findings (17).
When -catenin signaling was reduced, co-stimulation of ALP
activity byWnt3a and heparin was also greatly diminished (Fig.
4D). The Wnt3a-heparin combination remained stimulatory
for ALP activity, albeit less potent in the -catenin-depleted
cells (3.1-fold in control cells versus 1.8-fold in siRNA treated
FIGURE 2. Wnt3a and heparin synergistically enhanced ALP activity.
MC3T3-E1 (A) or C2C12 (B) cells seeded at 30,000 cells/cm2 or rOB cells (C)
seededat 5000 cells/cm2were treatedwith either 50ng/mlWnt3a, increasing
doses of heparin (0.5 to 50g/ml) or the combinationof 50ng/mlWnt3awith
indicated doses of heparin. Untreated samples served as the control. ALP
activity was determined 72 h after treatment.
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cells). We note that Wnt3a and heparin together modestly
stimulatedALP activity (1.8-fold) (Fig. 4D) despite the suppres-
sion of -catenin-dependent LEF1/TCF activity (Fig. 4C).
However the residual presence of -catenin in siRNA-treated
cells (Fig. 4B) could also account for the 1.8-fold increase in
ALP activity (Fig. 4D), thus precluding a definitive interpreta-
tion. More importantly, the results of Fig. 4D indicate that the
-catenin pathway is required for co-stimulation byWnt3a and
heparin, although low levels of -catenin may not suffice for
enhancement of ALP activity, and a LEF1/TCF-independent
pathway may contribute to the synergistic activity of Wnt3a
and heparin. It remains to be determined whether a -catenin-
independent pathway contributes
to the synergistic activity of Wnt3a
and heparin.
BMP or FGF/FGFR Signaling Is
Dispensable for Wnt3a and Heparin-
stimulated ALP Activity—Heparin
may promote osteoblast maturation
by enhancing BMP-BMPR-Smads
signaling or FGF-FGFR-MAPK sig-
naling that may increase ALP activ-
ity and osteoblast differentiation
(Fig. 4A). Therefore, we investigated
if these signaling pathways were
potentiated by exogenous heparin
and account for the synergism with
Wnt3a that resulted in osteoblast
differentiation. We first assessed if
co-treatment ofWnt3a and heparin
activated BMP signaling as reflected
by Smad-dependent activation of
the promoter of the Id1 gene, a
direct target of BMP signaling (36).
We observed that Id1 transcription
was dramatically induced by 100
ng/ml BMP2, but Wnt3a and hepa-
rin alone or together clearly did not
stimulate Id1 promoter activity
(supplemental Fig. S2A). Further-
more, ALP activation byWnt3a and
heparin was not diminished by
Smad4 siRNA (supplemental Fig.
S2, B and C), thus excluding BMP
signaling as a pathway that contrib-
utes to the co-stimulation of ALP
activity by Wnt3a and heparin. In
examining FGF signaling, Wnt3a
and heparin together were able to
increase the expression of FGFR2
and FGFR3, but not FGFR1, at the
mRNA or protein levels (supple-
mental Fig. S2, D and E). However,
suppression of the kinase activity of
FGFRs using the selective chemical
inhibitor SU5402 failed to decrease
the ALP activity induced by Wnt3a
and heparin (supplemental Fig.
S2F). Moreover, the ERK pathway that mediates osteoblast dif-
ferentiation in response to FGF/FGFR (37, 38)was not activated
by Wnt3a and heparin (supplemental Fig. S2G). Collectively,
these data indicate that neither BMPs nor FGFs account for
osteogenic stimulation by the combination of Wnt3a and
heparin.
Wnt3a and Heparin Cooperate to Induce Sustained Activa-
tion of the PI3K/Akt Pathway to Stimulate ALP Activity—The
PI3K/Akt pathway plays an important role in osteoblast differ-
entiation and synergizes with Wnt signaling to determine
osteoblastic cell fate (25, 39). The regulatory subunit of PI3K,
p85, is up-regulated within 24 h after a pulse of exogenous
FIGURE 3.Sulfationonheparin chain is important for its bindingaffinity andbiological activity.A, shown
is the structure of disaccharide units of heparin. B, Wnt3a was incubated with heparin-Sepharose in the pres-
ence or absence of heparin or desulfated heparin, and theWnt3a bound to the Sepharose beadswas detected
byWesternblot analysis. The intensity ofWnt3awasquantifiedbydensitometry, and thebar graphplottedwas
shown above the blot.C, increasing doses of unmodified heparin or desulfated heparin (0.05–150g/ml)were
immobilizedonheparin/GAGbindingplates before 50ng/mlWnt3awas applied. The amount ofWnt3abound
by these heparinswas determined by enzyme-linked immunosorbent assay as described under “Experimental
Procedures.” D, MC3T3-E1 cells were stimulated with 50 ng/ml Wnt3a alone or Wnt3a pre-incubated with 50
g/ml heparin or desulfated heparins for 72 h followed by the determination of ALP activity.
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Wnt3a andheparin (Fig. 5A). Consistently, the amount of phos-
phorylated p85 and phosphorylated Akt were both increased,
whereas total Akt protein levels remained unchanged (Fig. 5A).
Increased phosphorylation of PI3K or Akt upon Wnt3a and
heparin administration was not apparent until after 6 h but
occurred simultaneously with elevation of p85 protein levels
(data not shown), suggesting involvement of an intermediary
factor(s) (see “Discussion”). Notably,Wnt3a alone increases the
protein level of p85 and subsequent activation of Akt, but the
combination of Wn3a and heparin further enhanced the activ-
ity of the PI3K/Akt pathway (Fig. 5B). To determine whether
the PI3K/Akt pathway mediates the osteogenic activity of
Wnt3a and heparin, we disrupted PI3K kinase activity using the
chemical inhibitor LY294002. LY294002 completely abolished
the phosphorylation of Akt (Fig. 5C) when applied to
MC3T3-E1 cells 1 h before co-treatment withWnt3a and hep-
arin. Notably, inhibition of PI3K activity eliminated Wnt3a-
heparin-induced ALP activity (Fig. 5D). Furthermore, silencing
of p85 and Akt by their specific siRNAs also disabled Wnt3a-
heparin-stimulated ALP activity (Fig. 5, E and F). We conclude
that Wnt3a and heparin stimulate the PI3K/Akt pathway via
up-regulation of p85-PI3K to enhance ALP activity.
Wnt3a and Heparin Synergistically Increase the Expression
and Activity of RUNX2—We next examined if the combination
of Wnt3a and heparin affected other osteogenic biomarkers.
RUNX2 and osterix are transcription factors crucial for osteo-
blast differentiation. ALP, bone sialoprotein, and osteocalcin
are osteoblast phenotypic markers up-regulated in a defined
temporal sequence. MC3T3-E1 cells treated for 3 days with
Wnt3a and heparin expressed higher mRNA levels of bone-
related biomarkers compared with either Wnt3a or heparin
alone (Fig. 6A), indicating significant stimulation of osteogenic
differentiation. Increased ALP mRNA levels corroborated the
elevations of ALP activity that we observed throughout our
studies (see Fig. 2A). For comparison, in contrast to the overall
synergistic up-regulation of osteogenic genes, the mRNA level
of c-Myc, a transcriptional regulator controlling cell prolifera-
tion, was not affected byWnt3a and heparin (Fig. 6A). In addi-
tion, a panel of genes involved in cell cycle progression ex-
hibited different parallel or opposite patterns of expression
compared with mRNA levels for osteogenic biomarkers (see
supplemental Fig. S1).
RUNX2 plays a critical role in osteoblast differentiation and
induces the expression of other genes that regulate or charac-
terize osteoblast phenotypes, including osterix, ALP, bone sia-
loprotein, and osteocalcin (40, 41). Consistent with its
increasedmRNA levels, RUNX2 protein and its transcriptional
activity on a RUNX2-responsive promoter were also enhanced
upon co-stimulation withWnt3a and heparin (Fig. 6, B and C).
Although either Wnt3a or heparin is capable of increasing the
expression and activity of RUNX2 to a limited extent, these
synergizing agents are a particularly potent stimulus for
RUNX2 when administered in combination.
RUNX2 Activity Is Required for Wnt3a and Heparin-stimu-
lated ALP Activity—The central role of RUNX2 in osteoblast
differentiation as well as its functional links withWnt signaling
(19) and proteoglycan gene expression (20, 21) suggest that this
transcription factormay be an importantmediator of the osteo-
genic activity ofWnt3a and heparin. Upon RUNX2 silencing by
specific siRNA inMC3T3-E1 cells, Wnt3a (50 ng/ml) and hep-
arin (50g/ml) were unable to stimulate ALP activity (Fig. 7A).
A similar loss of their control over ALP was observed in
RUNX2/ osteoprogenitor cells (Fig. 7B), which were derived
by immortalization of calvarial osteoblasts from RUNX2
knock-out mice (28, 42). However, forced expression of wild
type RUNX2 protein in RUNX2/ cells recovered the respon-
siveness of ALP activity to co-stimulation byWnt3a (50 ng/ml)
and heparin (50g/ml) (Fig. 7B). Because the responsiveness to
different heparin concentrations varied among the cell types,
we further conducted a systematic measurement of ALP activ-
ity in RUNX2/ cells or RUNX2/ cells complemented with
wild type RUNX2 after treatment with Wnt3a and/or various
FIGURE 4. -Catenin mediated Wnt3a-heparin-stimulated ALP activity.
A, shown is an illustration of the interaction of heparin with Wnt and other
growth factor signaling pathways that may regulate Wnt dependent osteo-
blast proliferation and differentiation. IGFBP, IGF-binding protein; BSP, bone
sialoprotein; OCN, osteocalcin; OSX, osterix; CKI, cyclin-dependent kinase
inhibitor. B, MC3T3-E1 cells were transfected with scramble siRNA or -cate-
nin siRNA for 24 h. The protein level of -catenin was assessed by Western
blotting. C, cells transfected with -catenin siRNA or scramble siRNA were
further transfected with TOP-FLASH or FOP-FLASH together with Renilla-LUC
DNA. 6 h later the cells were exposed to 50 ng/ml Wnt3a for 24 h, and the
luciferase activity was measured. D, parallel cultures of -catenin
siRNA-transfectedMC3T3-E1 cells were treated with a combination ofWnt3a
(50 ng/ml) and heparin (50 g/ml) for 72 h, and ALP activity assessed.
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doses of heparin (Fig. 7, C and D). In RUNX2/ cells, either
Wnt3a or heparin at different dosage or their combination was
unable to stimulate ALP (Fig. 7C). In contrast, upon re-intro-
duction of RUNX2 into this cell line, a dose-dependent increase
of ALP activity was observed upon co-treatment with Wnt3a
and heparin, and maximal ALP stimulation (1.7-fold) was
achieved by the combination of 5 g/ml heparin and 50 ng/ml
Wnt3a (Fig. 7D). This robust but quantitatively modest
co-stimulatory effect may be less pronounced than in other cell
types, because not all cells are expected to express exogenous
RUNX2 upon transfection. Wild type primary osteoprogenitor
cells derived from rat calvaria (rOB) were also included in
this study for comparison with
RUNX2/ cells. Similar to other
osteoblastic cells, rOB exhibited
enhanced ALP stimulation by
Wnt3a and heparin (Fig. 2C). The
ability to selectively eliminate and
restore osteogenic signaling by
Wnt3a and heparin depending on
the absence or presence of RUNX2
clearly demonstrates that RUNX2 is
a critical and integral part of the
Wnt3a-heparin signaling network.
Stimulation of RUNX2Activity by
Wnt3a andHeparin IsMediated via
the PI3K/Akt Pathway—Recent
studies have indicated that PI3K/
Akt regulates RUNX2 (39, 43), and
our study shows that PI3K/Akt is a
prominent pathway contributing to
the Wnt3a and heparin stimulation
of RUNX2. To test the hypothesis
that PI3K/Akt is a component of the
same signaling axis and rate-limit-
ing for RUNX2 activity, we dis-
rupted PI3K kinase activity using
LY294002 at a dose (10 M) that
was sufficient to suppress PI3K sig-
naling (see Fig. 5C). Notably, inacti-
vation of PI3K/Akt eliminated both
basal and Wnt3a-heparin induced
RUNX2 protein expression (Fig.
8A). This finding was further con-
solidated using siRNAs to reduce
Akt expression. RNA interference
forAkt reducedWnt3a-heparin-de-
pendent induction of RUNX2 (Fig.
8B). Moreover, LY294002 dramati-
cally blocked the RUNX2 transcrip-
tional activity that was normally
enhanced by the combination of
Wnt3a and heparin (Fig. 8C). For
comparison, LY294002 only mini-
mally affects -catenin-dependent
LEF1/TCF activity (Fig. 8D), sug-
gesting that the previously identi-
fied Akt/glycogen synthase kinase
3/-catenin/LEF axis (25) is not the primary pathway that
transduces Wnt3a-heparin signaling in MC3T3-E1 cells. We
conclude that Wnt3a and heparin cooperatively promote
osteoblast maturation in part by inducing PI3K/Akt signaling
and enhancing RUNX2 function.
DISCUSSION
The control of osteoprogenitor cell growth and differen-
tiation, which is essential for bone formation, is exercised in
large part by bone-related growth factors that interact with
their cognate plasma membrane receptors. Heparan sulfate
proteoglycans, which are abundant on the cell surface and in
FIGURE 5. PI3K/Akt pathway is required for Wnt3a-heparin stimulated ALP activity. A and B, p85-PI3K
and Akt protein levels as well as their phosphorylation status were measured in MC3T3-E1 cells treated
with either 50 ng/ml Wnt3a, 50 g/ml heparin, or their combination. The relative amount of protein was
evaluated by densitometry analysis of the blot in B. C, MC3T3-E1 cells were treated with different concen-
tration of LY294002 for 1 h before the level of phosphorylated Akt (the direct target of activated PI3K) was
assessed by Western blotting. D, cells preincubated 1 h with 10 M LY294002 were stimulated with Wnt3a
and heparin for 72 h and then assayed for ALP activity. E and F, MC3T3-E1 cells were transfected with
scramble siRNA or siRNA specific for p85 or Akt for 24 h before stimulation with Wnt3a and heparin. The
siRNA knock-down efficiency was evaluated by Western blot analysis. ALP activity was measured 72 h
post-stimulation.
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the extracellular matrix, have emerged as major co-regula-
tors controlling signaling pathways in osteogenic cells (44).
Heparan sulfates increase the expression of bone-related
biomarkers and maintain BMP signaling, and studies have
suggested that this family of sugar-based compounds
orchestrates the transition from proliferation to differentia-
tion (3, 33, 44). Supporting this view, our study demonstrates
that heparin strongly synergizes with Wnt3a and selectively
stimulates the osteogenic but not mitogenic potential of
Wnt3a. As natural polysaccharides, heparan sulfates and
heparin are chemically stable and well tolerated clinically.
Such advantages make their exogenous application an
attractive approach to augment the efficacy of osteogenic
growth factors during bone tissue wound healing. Increased
understanding of their mechanism of action to co-stimulate
downstream signaling pathways, which respond to bone
related growth factors, is a prerequisite to their exploitation
in skeletal regenerative medicine.
Accumulating evidence has demonstrated that different
sulfate groups within HS/heparin contribute unequally to
their interactions with target proteins, so providing a molec-
ular basis for selective recognition of distinct ligands (33,
45–47). Heparin forms a ternary complex with FGF2
through N- and 2-O-sulfate groups and with FGFRs via 6-O-
sulfate groups (1, 48–51). Such interactions enhance the rec-
ognition of the cognate FGFRs and subsequent activation of
downstream signaling pathways. Interestingly,N-sulfation is
also essential for HS binding to both BMP7 and platelet-
derived growth factor-BB, whereas O-sulfation (2-O) is less
important (33, 45). A key finding of our study is that N-sul-
fation is more crucial than O-sulfation for heparin-Wnt3a
interactions, albeit both are important for maximal binding
affinity and biological activity. Although there are no iden-
tified heparin-binding domains in the Wnt receptors Friz-
zled or LRPs, heparin binds to sFRP1 (secreted Frizzled-re-
lated proteins 1), which interacts directly with Wnts and
FIGURE 6.Wnt3a and heparin synergistically increased the expression
and activity of osteogenic biomarkers. A, the mRNA levels of several
osteogenic transcription factors and osteoblast phenotypic markers were
assessed by TaqMan real-time PCR. The samples were prepared in tripli-
cate, and the data represent the mean  S.E. of three independent
experiments. OCN, osteocalcin; OSX, osterix; REU, relative expression unit.
B, Western blot analysis of the protein level of RUNX2 after MC3T3-E1 cells
were treated with 50 ng/ml Wnt3a, 50 g/ml heparin, or their combina-
tion for 72 h. C, 6xOSE-LUC reporter assay was performed to examine
RUNX2 transcription activity as described under “Experimental
Procedures.”
FIGURE 7. RUNX2 was required for Wnt3a-heparin stimulated ALP activ-
ity. A, MC3T3-E1 cells deficient in RUNX2 by RUNX2 siRNA transient transfec-
tion were challenged by the combination of Wnt3a and heparin. Then the
efficiency of RUNX2 silencing, and the effect on ALP activity was evaluated
after 72 h. B, the responsiveness of ALP activity to Wnt3a and heparin was
assessed in RUNX2/ cells. Wild type RUNX2 vector was then re-introduced
into RUNX2/ cells. The efficacy of forced-expression of RUNX2 was evalu-
ated, and theALP activitywas again examined in RUNX2/ cells treatedwith
Wnt3a and heparin after recovery of RUNX2 expression. C and D, RUNX2/
cells or RUNX2/ cells transfected with wild type RUNX2 were seeded at
2500 cells/cm2and then treatedwitheither 50ng/mlWnt3a, increasingdoses
of heparin (0.5 to 50 g/ml), or the combination of 50 ng/ml Wnt3a with the
indicateddosesofheparin.Untreated samples servedas controls. ALPactivity
was determined 72 h after treatment.
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Frizzled (52). Thus, it has been proposed that heparin
bridges Wnt and Frizzled by forming a ternary complex sim-
ilar to the FGF-HS-FGFRmodel (26). Notably, heparin needs
O-sulfation but not N-sulfation to regulate sFRP1 (53, 54).
Thus, N-sulfate groups might be a universal moiety for hep-
arin-ligand binding, whereas O-sulfate groups (2-O, 6-O, or
both) may be more crucial for heparin-receptor binding
(Fig. 9B).
IGFs are powerful ligands that activate the PI3K/Akt path-
way to promote osteoblast differentiation. However, heparin
does not enhance IGF-1-stimulated ALP activity inMC3T3-E1
cells (supplemental Fig. S3A); it appears that heparin potenti-
ates neither IGF-1 signaling at the cell surface nor IGF-1-re-
lated intracellular cross-talk with Wnt/-catenin. Rather,
heparin synergizes with Wnt3a in a co-stimulation of
MC3T3-E1 differentiation by up-regulating PI3K protein,
and both compounds additively induce Akt phosphorylation
after an initial delay (i.e. 6–24 h post-stimulation). Akt acti-
vation was diminished by cycloheximide administration
(supplemental Fig. S3B), suggesting that new protein synthe-
sis (i.e. generation of a proxy factor) is involved. Indeed,
Wnt3a but not heparin acts to increase p85 protein, although
the Wnt3a-dependent increase is enhanced by heparin and
results in a prominent elevation of Akt phosphorylation. We
propose that heparin magnifiesWnt3a activity by sensitizing
p85-PI3K/Akt signaling that together with -catenin-LEF1/
TCF signaling promotes osteoblast maturation.
We have observed that heparin, even on its own, increases
the phosphorylation of Akt. There are several possible mech-
anisms that could account for how heparin/heparan sulfate
activates PI3K/Akt signaling. Heparin can bind to integrins
in vitro and ex vivo (55). Integrins, as the receptors that
mediate cell attachment to the extracellular matrix and in
some cases to other cells, associate with focal adhesion
kinase to induce several intracellular signaling cascades and
so transduce the signals between the cell and its environ-
ment. In osteoblasts, the PI3K/Akt pathway functions down-
stream of the extracellular stimuli that activate integrin/fo-
cal adhesion kinase (56). Alternatively, heparin may interact
with heparin binding epidermal growth factor to activate the
PI3K pathway, as has been found in other cell/tissue types
(57, 58). Further investigations are required to distinguish
among these possibilities.
Unlike C2C12 myoblastic mesenchymal progenitor cells
that are sensitive to the osteogenic activity of Wnt3a, pre-
committed MC3T3-E1 osteoblasts exhibit only a minimal
increase in ALP activity upon Wnt3a stimulation. Our
results show that -catenin signaling is required for the basal
maintenance and co-stimulation of ALP activity by Wnt3a
and heparin in MC3T3-E1 cells. Heparin enlarges the osteo-
genic potential of Wnt3a/-catenin by synergistically stim-
ulating the PI3K/Akt/RUNX2 axis. Akt may increase -cate-
nin levels by inhibiting glycogen synthase kinase 3 (25),
although we ourselves did not observe this reciprocal feed-
back regulation. We, therefore, postulate that PI3K/Akt and
-catenin represent two separate mechanisms that are capa-
ble of promoting osteoblast differentiation. In support, a
recent study has also described the existence of the -cate-
nin-independent Wnt signaling that activates RUNX2 in
osteoblasts (59).
In summary, we have demonstrated that soluble extracellular
glycosaminoglycans such as heparin can strongly and selec-
tively potentiate Wnt signaling to promote maturation of cells
within the osteoblast lineage. The maximal osteogenic activity
of Wnt3a-heparin requires both canonical -catenin and non-
canonical PI3K/Akt/RUNX2 signaling. This novel role of hep-
arin in specifically enhancing Wnt-dependent osteogenic dif-
ferentiation offers an opportunity to develop new strategies for
the healing of bone defects.
FIGURE 8. PI3K/Akt pathway mediated the effect of Wnt3a and heparin
onRUNX2activity inMC3T3-E1 cells.A, 10M LY294002was applied to the
cells 1 h before co-treatment with Wnt3a and heparin. The level of RUNX2
proteinwas determined72h later. B, 24 h after cellswere transfectedwith the
specific siRNA against Akt or scramble siRNA, they were stimulated with
Wnt3a and heparin for 72 h. The reduced level of Akt and RUNX2 was exam-
ined by Western blot analysis. C, cells were transfected with 6xOSE-LUC and
Renilla-LUCvectors. After 24h, cellswere challengedwith 10MLY294002 for
1 h preceding the stimulationwithWnt3a and heparin. The luciferase activity
assay was then carried out 48 h later. D, TOP-FLASH or FOP-FLASH together
with Renilla-LUC vector was forcibly expressed in cells. 6 h later cells were
treated with 10 M LY294002 for 1 h before the co-treatment of Wnt3a and
heparin for another 24 h. The luciferase activity was then determined. The
doses of Wnt3a and heparin used above were 50 ng/ml and 50 g/ml,
respectively.
FIGURE 9. A, shown is a diagram of the signaling mechanism depicting the
synergistic activation of ALP byWnt3a and heparin. B, shown is an illustration
of the different role ofO-sulfate andN-sulfate groups of heparin in binding to
Wnts compared with FGF2. The thickness of the line between the sulfate
groups of heparin and the ligand indicates the strength of binding affinity:
thinner line, lower affinity; thicker line, higher affinity.
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